Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The beta-thalassaemias have a major global impact on health and mortality. Allogeneic haemopoietic stem cell transplantation is the only approach that may lead to a cure but this approach is not available to most patients. The mainstay treatment for the majority remains life-long blood transfusion in combination with a rigorous regime of iron chelation. Improved understanding of the pathophysiology and molecular basis of the disease has provided clues for more effective strategies that aim to correct the defect in beta-globin chain synthesis at the primary level or redress the alpha/beta-globin chain imbalance at the secondary level. Improved understanding of the molecular basis of the disease complications, such as iron overloading, has also provided clues for potential molecular targets at the tertiary level.

Original publication

DOI

10.1111/j.1365-2141.2006.06408.x

Type

Journal article

Journal

Br J Haematol

Publication Date

02/2007

Volume

136

Pages

353 - 365

Keywords

Chelating Agents, Chromosomes, Human, Pair 11, Genetic Therapy, Globins, Hematopoietic Stem Cell Transplantation, Humans, Iron Overload, Oligonucleotides, Antisense, RNA Interference, beta-Thalassemia